Controlled double-blind trial with Baryta carbonica 15 CH versus placebo in a group of hypertensive subjects confined to bed in two old people's homes

1987 ◽  
Vol 76 (03) ◽  
pp. 114-119 ◽  
Author(s):  
M. Bignamini ◽  
A. Bertoli ◽  
A.M. Consolandi ◽  
N. Dovera ◽  
M. Saruggia ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Active Drug ◽  
Point Of View ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Positive Results ◽  
Old People's Homes

AbstractTaking into account the toxicology of soluble barium salts, the authors treated 32 hypertensive subjects who were confirned to bed in two old people's homes with Baryta carbonica 15 CH versus placebo in a randomized double-blind study. Seventeen patients were given Baryta carbonica and 15 placebo. Taking the groups as a whole, no statistically significant differences were found between the effects of placebo and active drug on the blood pressure. But the four subjects who had been prospectively considered sensitive and were treated with Baryta carbonica gave strongly positive results. Some interesting conclusions were arrived at both from the general medical and the homœopathic point of view.

A Double-Blind Trial of Terfenadine and Placebo in Hay Fever Using a Substitution Technique for Non-Responders

1980 ◽  
Vol 8 (6) ◽  
pp. 404-407 ◽  
Author(s):  
G Kagan ◽  
E Dabrowicki ◽  
L Huddlestone ◽  
T R Kapur ◽  
P Wolstencroft
Keyword(s):  
Active Drug ◽  
Hay Fever ◽  
Blind Study ◽  
Skin Tests ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Reference Drug ◽  
Blind Trial ◽  
Novel Technique

A double-blind study of terfenadine and placebo in 110 patients suffering from hay fever (confirmed by skin tests) was conducted. A novel technique was applied using an escape envelope containing a reference drug which could be taken under controlled conditions if, after 48 hours, the patient experienced no relief. Significantly more patients on placebo opened the envelope than patients taking the active drug. Terfenadine was demonstrated to be an effective drug in hay fever and produced no more drowsiness than placebo.

Comparison of a New Hypnotic (Finorgal) with Placebo in a Double-Blind Trial

1979 ◽  
Vol 7 (5) ◽  
pp. 387-390
Author(s):  
Gianni Baiotti
Keyword(s):  
Placebo Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
The Mean ◽  
Mean Time

The hypnotic effects of Finorgal (ethchlorvynol with diphenhydramine) were compared with those of placebo in a double-blind study with crossover of treatments in thirty-five hospital in-patients. During the four-week period of Finorgal treatment there was a significant reduction in the mean time elapsing between the administration of the hypnotic and the onset of sleep, and a significant increase in the duration of sleep, compared with the four weeks of placebo treatment. There was also a significant increase in the proportion of nights when the patients felt they had slept well, and in the incidence of morning ‘hangover’ and nocturnal confusion during the Finorgal treatment periods. Patients had to be actively woken in the morning significantly more often following Finorgal administration. In patients experiencing pain in the night there was a significant reduction in the occurrence of pain during the nights when Finorgal had been given.

Double Blind Study of Lecithin in Patients with Alzheimer's Disease

1981 ◽  
Vol 26 (6) ◽  
pp. 426-428 ◽  
Author(s):  
M. Fisman ◽  
H. Merskey ◽  
E. Helmes ◽  
J. Mccready ◽  
E.H. Colhoun ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serum Levels ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

Twenty-one patients with a diagnosis of Alzheimer's disease completed a double blind trial on lecithin 25 g daily. Equal improvement was noted in both the lecithin and placebo groups. Serum levels of lecithin measured 12-14 hours after its administration were also not increased compared with the levels in control patients. These findings of the ineffectiveness of lecithin inpatients with Alzheimer's disease are discussed in relation to the literature on this subject.

Double-Blind Study of Imipramine versus Phenelzine in Melancholias and Dysthymic Disorders

1987 ◽  
Vol 151 (5) ◽  
pp. 639-642 ◽  
Author(s):  
J. Vallejo ◽  
C. Gasto ◽  
R. Catalan ◽  
M. Salamero
Keyword(s):  
Major Depression ◽  
Blind Study ◽  
Dysthymic Disorder ◽  
Clinical Implications ◽  
High Dose ◽  
Double Blind Study ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
High Doses

In a 6-week double-blind trial, the efficacy of imipramine and high dose phenelzine were compared in the treatment of Major Depression with Melancholia, and Dysthymic Disorder (DSM-III). Both drugs were found to be equally efficacious in the treatment of 32 patients suffering from Major Depression. In 32 Dysthymic patients, phenelzine in high doses was found to be superior to imipramine. The clinical implications of these findings are discussed.

Does Oral Calcium Supplementation Lower High Blood Pressure? A Double Blind Study

1987 ◽  
Vol 5 (1) ◽  
pp. 67-71 ◽  
Author(s):  
Francesco P. Cappuccio ◽  
Nirmala D. Markandu ◽  
Donald R.J. Singer ◽  
Stephen J. Smith ◽  
Angela C. Shore ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Blood Pressure ◽  
Calcium Supplementation ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Oral Calcium

Hydromet: methyldopa + hydrochlorothiazide

1964 ◽  
Vol 2 (14) ◽  
pp. 55-56
Keyword(s):  
Blood Pressure ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Treatment Of Hypertension ◽  
Separate Tablets ◽  
Better Than

Hydromet (MSD) is a mixture of 250 mg methyldopa with 15 mg hydrochlorothiazide in a tablet offered for the treatment of hypertension. Both drugs may lower the blood pressure when it is raised. In a double-blind trial1 a combination of the two (given in separate tablets) was found to be better than either drug alone combined with a placebo. The dose of hydrochlorothiazide was 100 mg daily and the dose of methyldopa was increased from 1 to 2 G daily after the first week.

Flunarizine (10 and 20 mg) i.v. Versus Placebo in the Treatment of Acute Migraine Attacks: A Multi-Centre Double-Blind Study

Cephalalgia ◽  
1990 ◽  
Vol 10 (2) ◽  
pp. 77-81 ◽  
Author(s):  
Volker Pfaffenrath ◽  
Wolfgang Oestreich ◽  
Wolfgang Haase
Keyword(s):  
Blood Pressure ◽  
Visual Analogue Scale ◽  
Drug Administration ◽  
Analogue Scale ◽  
Blind Study ◽  
Response To Treatment ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Suitable Alternative

In a multi-centre, randomized double-blind study, the effect and tolerance of 10 and 20 mg flunarizine i.v. versus placebo was tested on 102 migraineurs with acute migraine attacks with and/or without aura. Thirty-seven patients received 10 mg flunarizine, 32 received 20 mg and 33 received placebo. The groups were comparable. Response to treatment was defined as pain reduction of at least 50% within 60 min on a visual analogue scale after i.v. drug administration. This effect was noted on 59.4% with 20 mg flunarizine, on 24.3% with 10 mg flunarizine and on 30.3% with placebo. The tolerance of flunarizine i.v. was similar to placebo. Blood pressure and pulse rate were not affected by flunarizine. All in all, 20 mg flunarizine i.v. appeared to be a suitable alternative for treatment of acute migraine attacks.

Sign in / Sign up

Export Citation Format

Share Document